181
Participants
Start Date
December 13, 2023
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2028
Lenacapavir Injection
Administered subcutaneously
Lenacapavir Tablet
Administered orally
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Administered orally
ICAP at Columbia University- Bronx Prevention Center, The Bronx
University of Pennsylvania, Division of Infectious Diseases Penn Prevention Research Unit, Philadelphia
Johns Hopkins Medicine Institute for Clinical and Translational Research, Clinical Research, Baltimore
West Virginia University, Morgantown
University of Miami - Converge Miami Building, Miami
Houston AIDS Research Team CRS, Houston
UCLA Vine Street Clinic, Los Angeles
UCSD AntiViral Research Center (AVRC), San Diego
Rutgers New Jersey Medical School, Department of Medicine, Newark
Lead Sponsor
HIV Prevention Trials Network
NETWORK
National Institute on Drug Abuse (NIDA)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Gilead Sciences
INDUSTRY